The clinical pharmacology of biotechnology products

Author

Year of publication

1991

Not available

Marcus M. Reidenberg, from the Department of Pharmacology and Medicine of the Faculty of Medicine of Cornell University (New York), edited this volume number 4 of the Esteve Foundation Symposia series. The new molecular and cell biology techniques provide different opportunities to develop new agents for the diagnosis, treatment and prevention of diseases. Clinical pharmacologists, physicists and investigators of this new biology met at the international symposium organized by the Esteve Foundation in 1990 to find ways to extrapolate the potential of modern biomedical science to reality in order to improve people’s health.

Chapters
Introduction	M.M. Reidenberg	[wpdm id=145 type=”btn”]
List of participants		[wpdm id=146 type=”btn”]
1. Purification of Proteins: Converting a culture broth into a medicine	R.G. Werner	[wpdm id=123 type=”btn”]
2. Human insulin and its modifications	J.A. Galloway / R.E. Chance / K.S.E. Su	[wpdm id=124 type=”btn”]
3. the use of recombinant proteins in Aids research: Developtment of a CD4/GP120 binding assay	J. Mous / C. Manzoni / L. Dirckx	[wpdm id=125 type=”btn”]
4. FGF receptors as targets for drug development	C.A. Dionne / M. Jaye / J. Schlessinger	[wpdm id=126 type=”btn”]
5. Development of antagonists for IFNy and TNF	M. Steinmetz	[wpdm id=127 type=”btn”]
6. Proteins in search of a disease	L. Gauci	[wpdm id=128 type=”btn”]
7. Absorption of therapeutic peptides	B.R. Meyer	[wpdm id=129 type=”btn”]
8. Pharmacokinetics of human tissue-type plasminogen activator	P. Tanswell / E. Seifried / J. Krause	[wpdm id=130 type=”btn”]
9. Role of the Kidney in Eliminating Proteins and Peptides	D.C. Brater	[wpdm id=131 type=”btn”]
10. Possible problemas associated with Cytokine contamination of biotechnology products	A. Gearing / M. Wadhwa / R. Thorpe	[wpdm id=132 type=”btn”]
11. Selection of animal species and length of toxicity studies with recombinant proteins. Review of industry and regulators\’ approach and case history of Rec-Hirudin	P. Graepel / F. Pfannkuch / R. Hess	[wpdm id=133 type=”btn”]
12. Toxicological development of hematopoietic growth factors	H. Ronneberger	[wpdm id=134 type=”btn”]
13. Meaningful evaluation of biotechnology products	P. Juul	[wpdm id=135 type=”btn”]
14. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer	W. Aulitzky / G. Gastl / W.E. Aulitzky / J. Prick / C. Huber	[wpdm id=136 type=”btn”]
15. Tissue-Type Plasminogen Activator	H.R. Lijnen / D. Collen	[wpdm id=137 type=”btn”]
16. Erythropoietin	F. Valderrabano	[wpdm id=138 type=”btn”]
17. Clinical Pharmacology of Hirudin (HBW 023)	H.J. Roethig / J.S. Maree / B.H. Meyer	[wpdm id=139 type=”btn”]
18. Therapeutic actions of recombinant human granulocyte-Macrophage colony-stimulating factor (GM-CSF)	A. Ganser / D. Hoelzer	[wpdm id=140 type=”btn”]
19. Potential use of Peptide hormones in sport	J. Segura / R. de la Torre / R. Badia	[wpdm id=141 type=”btn”]
20. Costs of discovering, developing, manufacturing and marketing biotechnology products	W.M. Wardell	[wpdm id=142 type=”btn”]
21. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital	M. Levy / S. Penchas	[wpdm id=143 type=”btn”]
22. Biotechnological products, Can this commodity be afforded?	F. García Alonso	[wpdm id=144 type=”btn”]

10. Possible problemas associated with Cytokine contamination of biotechnology products
A. Gearing / M. Wadhwa / R. Thorpe
Download

22. Biotechnological products, Can this commodity be afforded?
F. García Alonso
Download

21. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital
M. Levy / S. Penchas
Download

20. Costs of discovering, developing, manufacturing and marketing biotechnology products
W.M. Wardell
Download

19. Potential use of Peptide hormones in sport
J. Segura / R. de la Torre / R. Badia
Download

18. Therapeutic actions of recombinant human granulocyte-Macrophage colony-stimulating factor (GM-CSF)
A. Ganser / D. Hoelzer
Download

17. Clinical Pharmacology of Hirudin (HBW 023)
H.J. Roethig / J.S. Maree / B.H. Meyer
Download

16. Erythropoietin
F. Valderrabano
Download

15. Tissue-Type Plasminogen Activator
H.R. Lijnen / D. Collen
Download

14. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer
W. Aulitzky / G. Gastl / W.E. Aulitzky / J. Prick / C. Huber
Download

13. Meaningful evaluation of biotechnology products
P. Juul
Download

12. Toxicological development of hematopoietic growth factors
H. Ronneberger
Download

The clinical pharmacology of biotechnology products Introduction
M.M. Reidenberg
Download

9. Role of the Kidney in Eliminating Proteins and Peptides
D.C. Brater
Download

8. Pharmacokinetics of human tissue-type plasminogen activator
P. Tanswell / E. Seifried / J. Krause
Download

7. Absorption of therapeutic peptides
B.R. Meyer
Download

6. Proteins in search of a disease
L. Gauci
Download

5. Development of antagonists for IFNy and TNF
M. Steinmetz
Download

4. FGF receptors as targets for drug development
C.A. Dionne / M. Jaye / J. Schlessinger
Download

3. the use of recombinant proteins in Aids research: Developtment of a CD4/GP120 binding assay
J. Mous / C. Manzoni / L. Dirckx
Download

2. Human insulin and its modifications
J.A. Galloway / R.E. Chance / K.S.E. Su
Download

1. Purification of Proteins: Converting a culture broth into a medicine
R.G. Werner
Download

The clinical pharmacology of biotechnology products List of participants
Download